On November 3, 2019, Health Canada published a MedEffect Notice advising of a higher risk associated with cardiovascular fatal outcomes, such as heart attacks, strokes, and heart-related deaths, in patients with gout and known cardiovascular disease treated with ULORIC (febuxostat), when compared to those treated with allopurinol

Uloric is used to lower serum uric acid levels in patients with gout who had an inadequate response or intolerance to another drug, allopurinal, or for those determined that allopurinol was inappropriate.